Review
Published on 05 Sep 2024
Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2024.1328728
- 12,335 views
- 18 citations
8 articles related to "G12c Mutation"
Articles
Mini Review
Published on 15 Sep 2023
Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer
in Gastrointestinal Cancers: Colorectal Cancer
Frontiers in Oncology
doi 10.3389/fonc.2023.1252516
- 16,780 views
- 36 citations
Original Research
Published on 28 Aug 2024
A real-world pharmacovigilance study of KRAS G12C mutation inhibitors based on the food and drug administration adverse event reporting system
in Predictive Toxicology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1418469
- 5,089 views
- 8 citations
Original Research
Published on 27 Nov 2025
Impact of KRAS G12C mutation on the efficacy of chemoradiotherapy in patients with unresectable stage II or III non-small cell lung cancer
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2025.1675825
- 1,811 views
Original Research
Published on 29 Nov 2022
Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer
in Gastrointestinal Cancers: Colorectal Cancer
Frontiers in Oncology
doi 10.3389/fonc.2022.1055019
- 7,363 views
- 22 citations
Case Report
Published on 13 Feb 2024
Case report: Successful treatment of advanced pulmonary sarcomatoid carcinoma with BUBIB-ALK rearrangement and KRAS G12C mutation by sintilimab combined with anlotinib
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2024.1269148
- 3,716 views
- 6 citations
Original Research
Published on 14 Jun 2024
Cost-effectiveness of sotorasib as a second-line treatment for non-small cell lung cancer with KRASG12C mutation in China and the United States
in Drugs Outcomes Research and Policies
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1348688
- 4,436 views
- 4 citations
Original Research
Published on 10 Aug 2022
Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50%
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.980765
- 6,178 views
- 15 citations